Reduction in the relative risk of invasive breast cancer among healthy female populations at increased risk, calculated in the NSABP P-1 trial. LCIS indicates lobular carcinoma in situ; AH, atypical hyperplasia; and NSABP, National Surgical Adjuvant Breast and Bowel Project.